To print: Select File and then Print from your browser's menu

Title: Nefazodone Improves Sleep Early In Depression Therapy

URL: http://bjp.rcpsych.org/cgi/content/abstract/180/6/528

British Journal of Psychiatry, 2002; 180: 528-535. "Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression"
06/11/2002 08:03:22 AM
By Elda Hauschildt

Nefazodone improves sleep during the early stages of treatment in patients with moderate to severe depression, in comparison with paroxetine. University of Bristol researchers from the England report the effects are seen within the first two weeks of therapy. Response then diminishes. They point out that the effects of antidepressants on sleep are clinically important. It is known that selective serotonin reuptake inhibitors disturb sleep and 5-hydroxytryptamine receptor-blocking compounds can enhance the quality of sleep. Investigators randomised 40 depression patients to either paroxetine (20 milligrams to 40 mg per day) or nefazodone (400 mg to 600 mg per day) for eight weeks. Objective and subjective quality of sleep and depression measures throughout the trial period. It was observed that nefazodone therapy significantly increased objective sleep efficiency and also increased total sleep time. Subjective sleep was improved on days three and 10 in patients in the nefazodone group. The researchers point out that sleep efficacy was decreased early in treatment for patients receiving paroxetine. Some sleep disruption remained at week eight. They also note that paroxetine, but not nefazodone, produced marked suppression of rapid eye movement (REM) sleep.

http://bjp.rcpsych.org/cgi/content/abstract/180/6/528

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.